BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

Pfizer and Astellas Expand FDA Approval of PADCEV Plus Keytruda Across All Muscle-Invasive Bladder Cancer Patients

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) announced that the U.S. Food and Dru...

July 14, 2026 | News

China Grants Priority Review to Leads Biolabs' Opamtistomig for Advanced Neuroendocrine Cancer

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced that the biologics license application (BLA) for Op...

July 13, 2026 | News

ACHP Launches Patient Advisory Council to Put Chronic Disease Voices at the Heart of Research

The Alliance of Community Health Plans (ACHP) is amplifying patients' voices on chronic disease research via its newly launched Patient Advisory Council. T...

July 13, 2026 | News

Lynk Pharmaceuticals Doses First Patient in Phase II Trial of Novel Vitiligo Therapy

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, ...

July 10, 2026 | News

Insilico Medicine Advances AI-Discovered IPF Drug Rentosertib into Phase III Trial

Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital peer-reviewed papers: the discovery-...

July 09, 2026 | News

Singapore Updates Wegovy Label to Include Higher-Dose Semaglutide Data Showing Up to 25% Weight Loss

Up to one in three participants on semaglutide 7.2 mg achieved at least 25% weight loss over 72 weeks Mean weight loss with semaglutide 7.2 mg reached 2...

July 09, 2026 | News

Europe Approves TEPKINLY Combination as First Bispecific-Based Second-Line Therapy for Follicular Lymphoma

TEPKINLY® (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Euro...

July 08, 2026 | News

J-Pharma Advances First-in-Class LAT1 Inhibitor Nanvuranlat into Global Phase 3 Trial for Biliary Tract Cancer

Pharma Co., Ltd., a clinical-stage biotechnology company focused on novel therapies targeting amino acid transporters, and Uniphar, a leading international...

July 08, 2026 | News

Arima Genomics Partners with Active Motif to Expand Global Access to Hi-C Research Portfolio

Agreement Part of Arima’s Long-Term Strategy to Focus on Core Diagnostic Platform and Tests Arima Genomics, Inc., a cancer diagnostics com...

July 07, 2026 | News

Immunomic Therapeutics Doses First Patient in Phase 1 Trial of saRNA Allergy Vaccine in Japan

First patient dosed less than one month after PMDA clearance, demonstrating rapid clinical execution Next-generation UNITE® saRNA-based immunother...

July 07, 2026 | News

Abu Dhabi DoH and MIT Koch Institute Partner to Advance AI-Enabled Oncology Research

The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate, and the MIT – Koch Institute for Integrative...

July 06, 2026 | News

Nona Biosciences and Lonza Partner to Develop Next-Generation BBB-Crossing Platform for CNS Therapies

Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery and development through innovative technology platforms, announced ...

July 03, 2026 | News

Ribo and Madrigal Achieve First siRNA Candidate Milestone for MASH Therapy

Suzhou Ribo Life Science Co., Ltd. (06938.HK), and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo"), in collaboration with M...

July 03, 2026 | News

Ever Supreme Advances Off-the-Shelf CAR-T Therapy CAR001 to Phase IIa After Positive Phase I Safety Review

Ever Supreme Bio Technology Co., Ltd. (TWSE: 6712) announced on June 28 that CAR001, its proprietarily developed, allogeneic, "off-the-shelf" CAR...

July 01, 2026 | News

Stay Connected